Spotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectives
Philipp Moog, Klaus Thuermel Abteilung für Nephrologie, Klinikum rechts der Isar, Technische Universität München, Munich, Germany Abstract: A 54-year-old patient presented to his general practitioner because of strong muscle pain in both thighs. Inflammatory parameters (...
Main Authors: | Moog P, Thuermel K |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-11-01
|
Series: | Therapeutics and Clinical Risk Management |
Online Access: | https://www.dovepress.com/spotlight-on-rituximab-in-the-treatment-of-antineutrophil-cytoplasmic--peer-reviewed-article-TCRM |
Similar Items
-
Is rituximab “The Wonder Drug” for antineutrophil cytoplasmic antibodies-associated vasculitis?
by: Saket Jha, et al.
Published: (2019-01-01) -
Severe Infections following Rituximab Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
by: Zhi-Ying Li, et al.
Published: (2020-08-01) -
Renal Transplantation in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Current Perspectives
by: Zdenka Hruskova, et al.
Published: (2020-02-01) -
Treatment of Aggressive Antineutrophil Cytoplasmic Antibody–Associated Vasculitis With Eculizumab
by: Noah Huizenga, et al.
Published: (2020-04-01) -
Stress and Disease Onset in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
by: Christina V. Golemati, et al.
Published: (2017-12-01)